Verona Pharma plc (VRNA)
Oct 7, 2025 - VRNA was delisted (reason: acquired by MRK)
106.91
+0.12 (0.11%)
Inactive · Last trade price
on Oct 6, 2025
Company Description
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs.
The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma.
Verona Pharma plc was formerly known as Isis Resources plc and changed its name to Verona Pharma plc in September 2006.
The company was incorporated in 2005 and is based in London, the United Kingdom. As of October 7, 2025, Verona Pharma plc operates as a subsidiary of Merck Sharp & Dohme LLC.
Verona Pharma plc
| Country | United Kingdom |
| Founded | 2005 |
| IPO Date | Apr 27, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 209 |
| CEO | David Zaccardelli |
Contact Details
Address: 3 More London Riverside London, SE1 2RE United Kingdom | |
| Phone | 44 20 3283 4200 |
| Website | veronapharma.com |
Stock Details
| Ticker Symbol | VRNA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001657312 |
| CUSIP Number | 925050106 |
| ISIN Number | US9250501064 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Scott Zaccardelli Pharm.D. | President, Chief Executive Officer and Executive Director |
| Mark W. Hahn CPA | Chief Financial Officer |
| Andrew Fisher | General Counsel |
| Dr. Kathleen A. Rickard M.D. | Chief Medical Officer |
| Victoria Stewart | Senior Director of Investor Relations and Communications |
| Matthew Casbon | Vice President of Sales, Marketing and Training |
| Ostra Jewell | Senior Vice President of Human Resources |
| Dr. Tara Rheault M.P.H., Ph.D. | Chief Development Officer |
| Christopher Martin | Chief Commercial Officer |
| Caroline Diaz | Chief Regulatory Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 7, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 7, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 7, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 7, 2025 | POSASR | Filing |
| Oct 7, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 7, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 7, 2025 | POS AM | Post-Effective amendments for registration statement |
| Oct 7, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 7, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 7, 2025 | 25-NSE | Filing |